12:00 AM
 | 
May 11, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fortigel testosterone regulatory update

FDA accepted a complete response from ProStrakan to a 2003 not approvable letter for Fortigel testosterone to treat male hypogonadism. The...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >